INTRODUCTION
Head and neck cancer (HNC) is one of the most prevalent cancers worldwide. 1 Despite improvements in diagnosis and treatment in recent decades, the patient survival rate has not significantly changed because of the development of distant metastases and therapeutic resistance. [2] [3] [4] It is essential to more deeply investigate the mechanism of this disease and to develop a more effective therapeutic modality. Recently, accumulating evidence suggests that tumors contain a small subpopulation of cells, known as tumor initiating cells or cancer stem cells (CSCs) , that possess characteristics of both stem cells and cancer cells, including the properties of self-renewal, stress tolerance, propagation to differentiated progeny and expression of specific stem cell markers. [5] [6] [7] [8] [9] [10] However, CSCs differ from normal stem cells in their tumorigenic activity. Although CSCs represent a small percentage of the overall tumor population, they are the cells with highly invasive ability and resistance to conventional cancer treatments such as chemotherapeutic agents or radiation. [5] [6] [7] [8] [9] [10] Therefore, elimination or CSCs may be the ultimate approach to radically cure cancer. Subpopulations of CSCs have been isolated by specific expression of cell-surface markers, such as CD44 and CD133 in squamous cell carcinoma. [11] [12] [13] [14] The CSCs of HNC (HN-CSC) have been characterized as CD24 À CD44 þ . 14, 15 These CD24 À CD44 þ cells have also been reported to exhibit CSC properties in other cancers such as breast and prostate cancers. [16] [17] [18] [19] [20] However, the regulatory mechanism involved in the conversion of CD24 À CD44 þ phenotype is still not clear. Grp78 (glucose-regulated protein of 78 kDa), also named as Hsp70-5/Bip, is traditionally regarded as an endoplasmic reticulum chaperone functioning in cytoprotection by facilitating protein folding and assembly in response to stress signaling. 21, 22 It has a critical anti-apoptotic role leading to the modulation of chemosensitivity. 21, 22 Recent reports suggest that Grp78 has more roles than what was originally thought. For example, Grp78 is required for survival during mouse embryonic development. 23 This molecule is also overexpressed in many cancers and actively regulates multiple malignant phenotypes including tumor growth and invasion. [24] [25] [26] Therefore, we investigated whether Grp78 participating a role on CSC regulation, especially on the CD24 À CD44 þ stemness phenotype of HNC. We found that Grp78 facilitated the formation of HN-CSC, as demonstrated by active contribution of chemo-radioresistance, cell invasion, stemness property, epithelial-mesenchymal transition (EMT) and CD24 À CD44 þ cell conversion. Silencing Grp78 expression reverses tumorigenesis and increases survival in xenografted mice with CD24 À CD44 þ cells, along with the suppression of stem cell molecules. Grp78 may serve as a molecular target that can be further developed for eradication of refractory HNC.
MATERIALS AND METHODS

Cell culture
Six HNC cell lines were used: Fadu, Detroit, OECM1, SAS, BM1 and BM2, which were maintained as described previously. [27] [28] [29] [30] Briefly, cells were grown at 37 1C in a humidified incubator containing 5% CO 2 . Sorted HN-CSCs were grown in culture medium supplemented with 10% FBS, 20 ng ml À 1 epidermal growth factor (EGF), 100 mg ml À 1 hydrocortisone and 10 ng ml À 1 human recombinant basic fibroblast growth factor (bFGF; Invitrogen, Carlsbad, CA, USA). All experiments were performed with cells of similar confluence. In Grp78 induction experiments, cells were treated with 5 mg ml À 1 tunicamycin (Sigma, St. Louis, MO, USA) for 16 h.
Chemicals and antibodies
Tunicamycin (Sigma) was dissolved in dimethylsulfoxide (1 mM stock solution) and then diluted in culture medium. For Grp78 induction, cells were treated with 1.5 mg ml À 1 tunicamycin for 16 h. Antibodies against Grp78 (clone N20), CK18 (clone DC18), Involucrin (clone N17), Nestin (clone 10C2), Oct-4 (clone X-23), fibronectin (clone P1H11) and Slug (clone G-18) were all purchased from Santa Cruz Biotechnology, CA, USA. The antibody against Actin (clone C4) was purchased from Millipore, Eschborn, Germany.
Silencing, overexpression and transfection of Grp78
The construction of the Grp78-siRNA plasmid and transfection experiments were performed as previously described. 24 In brief, the 22-nucleotide sense and antisense hairpin oligonucleotides were generated complementary to the Grp78 mRNA. The Grp78-siRNA was then cloned into the pTopo-U6 plasmid and transfected into cells using Lipofectamine 2000 reagent and OPTI-MEM medium (Invitrogen). In Grp78 overexpression experiments, cells were transfected with pCMV-Grp78 plasmids overexpressing Grp78 driven by the CMV promoter.
Western blot analysis
The protein extraction and immunoblot analyses were performed as previously described. 29 Briefly, proteins were extracted from cells using CHAPS lysis buffer containing protease inhibitor (protease inhibitor cocktail, Sigma). A total of 20 mg protein was separated by 8% SDSpolyacrylamide gel electrophoresis and transferred into nitrocellulose membranes. The membranes were blocked in 5% low-fat milk solution in phosphate-buffered saline with 0.05% Triton X-100. The membranes were hybridized with specific primary antibodies followed by incubation with secondary antibodies conjugated to horseradish peroxidase (Santa Cruz Biotechnology). Chemifluorescence reagents (ECL western blotting detection reagents, Millipore, Bedford, MA, USA) were used for visualization as per the manufacturer's instructions. Using the Gel Image System (Scion, MD, USA), the density of each band was determined after normalization to an actin control band.
Sorting of CD24
À CD44 þ CSCs and Grp78 þ cells by FACS analysis
To isolate CSCs from cell lines, FACS method was performed on a singlecell suspension after staining with fluorescein isothiocyanate-conjugated CD44 and phycoerythrin-conjugated CD24 antibodies (Biolegend, San Diego, CA, USA). CSCs were defined as the CD44 þ CD24 À population. To analyze Grp78 expression, a fluorescein isothiocyanate-conjugated Grp78 antibody (Stressgen, Ann Arbor, MI, USA) was used to measure Grp78 expression in parental cells and CSCs.
Parental cells and cells sorted for the surface markers of CD44, CD24 or Grp78 were suspended in PBS containing 1% FBS. Fluorescein isothiocyanate-conjugated CD44 antibodies, phycoerythrin-conjugated CD24 antibodies or fluorescein isothiocyanate-conjugated Grp78 antibodies were incubated with the cell suspension at the concentrations suggested by the manufacturer, and incubated at 4 1C protected from light for 60 min. Antibody-labeled cells were washed twice, suspended in PBS and assayed using FACSCalibur flow cytometry (BD, San Jose, CA, USA). Cells stained with isotype-matched antibodies and cells lacking primary antibody labeling were used as negative controls. After FACS, cells were immediately harvested for analysis.
Determination of radiosensitivity by the clonogenic survival assay Radiosensitivty was determined by the clonogenic survival assay as described previously. 31 Briefly, a total of 100 cells was seeded into a six-well plate and irradiated with serial doses of radiation (0-8 Gy). The cells were cultured for 7 days to allow colony formation. The colonies were stained with 2% crystal violet solution (10% paraformaldehyde and 2% crystal violet in PBS solution). Colonies 45 mm were counted and an average from three plates was used to define percent survival.
Determination of chemosensitivity by the MTS survival assay
Cell chemosensitivity was assessed using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS; Promega, Madison, WI, USA), according to the protocol suggested by the manufacturer. Briefly, a total of 2 Â 10 3 cells was seeded per well in a 96-well plate. Various concentrations of cisplatin ranging from 0 to 800 ng ml À 1 were added to each cell line. After a 24-hour incubation, 20 ml of MTS reagent was added to each well of a 96-well assay plate containing 100 ml of culture medium. After incubation in a humidified 5% CO 2 atmosphere at 37 1C for 30 min, the absorbance at 490 nm was measured with an enzyme-linked immunosorbent assay plate reader.
Cell invasion assay
The cell invasion assay was performed as described previously. 32 Briefly, a 1 Â 10 5 cell suspension cultured in MEM containing 1% FBS was seeded in the upper chamber of Matrigel-coated Millicell inserts (24-well plate, 8-mM l À 1 pore size, BD Biosciences, Bedford, MA, USA). The lower chamber was filled with DMEM supplemented with 10% FBS. After 3 days, the total number of cells that invaded the lower chamber was counted. All experiments were carried out in triplicate.
Immunofluorescent staining and confocal microscopy
Immunofluorescent staining was performed as previously described. 24 Briefly, the parental cells and siRNA-treated cells were grown on coverslips coated with 1% poly-L-lysine, fixed in 4% paraformaldehyde for 10 min, and then permeabilized with 0.5% Triton X-100 in PBS. After washing, cells were blocked with FBS for 1 h and incubated with anti-fibronectin and antiGrp78 primary antibodies overnight. Cells were washed and then incubated with fluorescein isothiocyanate-and phycoerythrin-conjugated secondary antibodies for 1 h at room temperature. After mounting cells with Vectashield H-1200 Mounting Medium (Vector Laboratories, Burlingame, CA, USA), the immunofluorescence was visualized under a Zeiss fluorescence microscope (Carl Zeiss, Thornword, NY, USA).
Cell sphere formation
For analysis of cell sphere formation, parental cells and the FACS-sorted cells were cultured in MEM containing 20 ng ml À 1 of EGF and 10 ng ml
of human recombinant bFGF (Invitrogen). The diluted cell suspension (10 000 cells per ml) was plated in each well of a Matrigel-coated six-well plate with 0.5 ml MEM. After 3 weeks, tumor spheres were visualized and 10 independent microscopic fields were enumerated.
Xenografts and in vivo tumorigenicity
The procedures for animal experiment were approved by the IACUC (Institutional Animal Care and Use Committee) of Chang Gung University and followed the guidelines of the research council for the caring and using of laboratory animals (approval no.: CGU 06-49, CGU 10-010). A minimal number of mice were used for the study and all efforts were made to minimize suffering. Establishment of xenograft tumors was performed as previously described. 27 Briefly, the immunodeficient mice (BALB/ cAnN.Cg-Foxn1nu/CrlNarl, 4-5 weeks old) were maintained under standard conditions according to institutional guidelines of animal management. These mice were randomly assigned to various groups of six mice. In each group, 4 Â 10 6 parental or FACS-sorted cells (
were subcutaneously injected into each mouse. In the Grp78-siRNA-treated group, mice were also injected intravenously with 25 mg of Grp78-siRNA plasmid in 25 ml of PBS 3 days after tumor cell injection, followed by repeated injections of the same dose, twice a week for total of 12 doses. Tumor volume was calculated as length Â width Â height and was measured every 2 days up to 7 weeks. All deaths were recorded during the study period and the data were used for survival analysis. Mice were subjected to CO 2 euthanasia according to institutional IACUC protocol at the end of this study. The changes in tumor size in each group were compared using an independent sample t-test. Survival curves were calculated by the Kaplan-Meier method, and the difference between groups was evaluated by the log-rank test. þ fraction was significantly increased in the Grp78 þ -sorted cells. A total of 1 Â 10 7 parental cells or Grp78 þ -sorted cells were stained with CD24 and CD44 antibodies conjugated to phycoerythrin or fluorescein isothiocyanate fluorescent dyes and subjected to flow cytometric analysis. For each sample, the percentages of the CD44 þ and CD24 À populations were calculated. (c) Grp78 expression was significantly increased in five CD24
À CD44 þ -sorted cell lines. The levels of Grp78 protein expression were determined in the parental and CD24 À CD44 þ cells by western blot analysis. Actin protein levels were determined as an internal control for protein expression. The relative density in each sample was indicated at the bottom of the band after normalization to the actin level in each individual sample. Pt, parental cells. Figure 2. Grp78 contributes to chemoresistance and radioresistance. The differential effects of radio-and chemoresistance were examined in various sorted cells: Grp78
þ cells transfected with Grp78-small interfering RNA (siRNA). (a) Chemoresistance was determined by the relative number of surviving cells after treatment with serial concentrations (0-800 ng ml À 1 ) of cisplatin for 24 h. In each sample, cell survival was examined using the MTS method as described in the Materials and methods section. (b) Radioresistance was determined by the clonogenic survival assay after treatment with various doses (0-8 Gy) of radiation for 7 days, as described in detail in the Materials and methods section. Targeting
Immunohistochemistry
The immunohistochemical assay was performed as previously described. 33 Briefly, tumors from xenografts were fixed in 10% neutralized buffered formaldehyde, embedded in paraffin and then stained with anti-Grp78, anti-nestin, anti-Oct-4 or anti-Slug antibodies (all were purchased from Santa Cruz Biotechnology as described above). The DakoCytomation REAL EnVision detection system (Dako, Carpinteria, CA, USA) was used for further staining and color development according to the manufacturer's instructions. The intensity of stained molecules was determined by microscopic examination. Figure 1a , the Grp78 þ fraction was significantly increased in the Grp78 silencing increased chemo-and radiosensitivity Since the resistance of chemo-radiotherapy was a characteristic of CSCs, 5-10 the potential effects of Grp78 on chemo-radiosensitivity were examined. The results of chemosensitivity in six HNC cell lines were shown in Figure 2a . Although varied between different cell lines, all cells showed the same trend. Between various sorted fractions, the CD24 À CD44 þ Grp78 þ cells showed highest resistance to cisplatin treatment. Comparing with the parent cells, the CD24
RESULTS
Positive association between CD24
þ cells were increased by 1.78-, 1.44-and 1.43-fold, respectively, at a dose of 800 ng ml À 1 in average of all cell lines. However, this refractory CD24 À CD44 þ Grp78 þ cells was subject to drug treatment upon Grp78 silencing. The chemosensitivity was increased by 1.51-and 1.80-folds at the doses of 400 and 800 ng ml À 1 , respectively.
The results of radiosensitivity in various sorted cells were determined in six HNC cell lines and two examples were shown in Figure 2b . 
Grp78
þ cells was subject to irradiation upon Grp78 silencing. The radiosensitivity dramatically increased to 3.7-and 113-folds at the 4 and 8 Gy, respectively.
Grp78 silencing inhibited cell invasion and reversed EMT As highly invasion was a characteristic of CSC, 5-10 the potential effect of Grp78 on cell invasion was examined. The invasion ability in various sorted cells was shown in Figure 3a . Recent reports indicate that a pronounced EMT is a characteristic of CSC that leads to cell invasion; [34] [35] [36] we therefore investigated whether Grp78 also regulated EMT. After knockdown Grp78 expression, the possible alterations of EMTassociated molecules were determined by western blot analysis. As shown in Figure 3b , Grp78 silencing increased the expression of E-cadherin and reduced the levels of N-cadherin, fibronectin and IQGAP1 scaffold protein in all three cell lines tested. The function of Grp78 in EMT was further supported by immunofluorescent staining and confocal microscopy. As shown in Figure 3c , Grp78 knockdown reduced fibronectin expression and broke down cell-extracellular matrix contacts as displayed by the mesenchymal-like nature of the contractile morphology. Taken together, these results suggest that Grp78 regulates cell invsion and the EMT process, important attributes of CSC.
Grp78 silencing suppressed cancer stemness, withdrew CD24 À CD44 þ cell conversion and induction differentiation phenotype To elucidate the function of Grp78 on the regulation of HN-CSC, we examined cell self-renewing potential in response to Grp78 modulation by determining the ability of cell sphere formation. Results were shown in Figure 4a . Grp78 silencing resulted to a substantial reduction of cell spheres in all cell line tested (down to B10% in average compared with the control). Conversely, the overexpression of Grp78 promoted cell sphere formation in both sphere number and size (1.7-fold increase in average compared with control). Furthermore, overexpression of Grp78 in the Grp78- 
þ cells transfected with Grp78-small interfering RNA (siRNA). Cell invasiveness was determined by the Matrigel invasion assay as described in the Materials and methods section. (b) Grp78 knockdown regulated epithelial-mesenchymal transition (EMT) marker molecules. Three cell lines (Fadu, Detroit and OECM1) were transfected with Grp78-siRNA or the vector plasmid as a negative control. Cellular protein was extracted and subject to western blot analysis to analyze the expression of EMT-associated molecules (E-cadherin, N-cadherin, fibronectin and IQGAP1). Actin protein levels were determined as an internal control for protein expression. The relative density in each sample was indicated at the bottom of the band after normalization to the actin level in each individual sample. Vt, vector plasmid-transfected cells; 78Si, Grp78-siRNA-transfected cells. (c) Cell morphology was altered upon Grp78 silencing. A total of 5 Â 10 5 Fadu cells were transfected with Grp78-siRNA or the vector plasmid for 16 h. Cells were then stained with antibodies against Grp78 and a fluorescein isothiocyanate-conjugated secondary antibody (green imaging) or fibronectin with Cy3-conjugated secondary antibody (red imaging) and cell morphology was observed by confocal microscopy. DAPI staining was also performed for nuclear localization and shown in blue. Merge imaging was shown to indicate the subcellular localization of the molecules.
silencing cells substantially rescued the number of spheres. These results suggest that Grp78 regulates cellular self-renewal capacity, a significant feature of HN-CSC.
To investigate whether Grp78 regulates CD24 À CD44 þ cell conversion, we altered Grp78 expression and examined the effects on the CD24 À CD44 þ fraction. Results were shown in Figure 4b . In the vector-transfected cells, the CD24 À CD44 þ fractions varied from 7.7 to 19.7% in all three cell lines. Grp78 silencing significantly decreased the CD24 À CD44 þ fraction down to only 1.9-4.1% of the total population, a suppression level between 21 (19.7-4.1%) and 24% (7.7-1.9%) in all three cell lines. To further elucidate the role of Grp78, a Grp78 activator, tunicamycin, was used. 37 Treatment by this activator rescued the Grp78-silencing effect, with a 2.6-fold (4.1-10.5%) to 3.7-fold (1.9-7.1%) increase in all three cell lines. These results suggest that Grp78 regulates the conversion of CD24 À CD44 þ HN-CSC cells. To extend these results on the molecular level, we examined the potential alterations of several CSC-associated molecules and differential markers after modulating Grp78 expression. Oct-4 [38] [39] [40] [41] and Slug, [41] [42] [43] [44] which have been reported to regulate stem cell attributes or control the EMT processing, were examined. The keratinocyte differentiation markers CK18 and involucrin were also examined. 45, 46 Results are shown in Figure 4c . Grp78 silencing significantly reduced Oct-4 and Slug expression down to o20% of the original levels, whereas CK18 (2.9-fold) and involucrin (2.8-fold) increased in all three cell lines. These results suggest that Grp78-expressing cells possess higher pluripotent ability, whereas Grp78 silencing suppresses cancer stemness potential and leads to a more differentiated phenotype.
Grp78 silencing restrained in vivo tumorigenicity, along with the inhibition of stem cell regulatory proteins To investigate the effects of Grp78 on in vivo tumorigenicity, we established xenografted tumor mice of Fadu cells sorted by
þ markers. All mice were in general health condition before transplantation of cancer cells. A total of 4 Â 10 6 cells were injected subcutaneously in a total of six BALB/c nude mice per group and monitored for a total of 7 weeks. Figure 5a shows the average tumor volume in these groups. The CD24 À CD44 þ cells showed significantly higher tumorigenicity, whereas CD24 þ CD44 þ cells showed similar tumorigenicity compared with the parental cells. The CD24 À
CD44
þ Grp78 þ cells demonstrated the highest ability to promote tumor growth with a 2.04-fold increase in tumor size compared with CD24 À CD44 þ cells at day 41 (Po0.001) and a 3.07-fold increase compared with the parental cells at day 41 (Po0.001). Marvelously, this aggressive tumor-forming ability by CD24 À
þ Grp78 þ cells was dramatically suppressed. Silencing Grp78 in the CD24 À CD44 þ Grp78 þ tumors through siRNA injection dramatically restrained tumor growth by over 95% after day 29 (Po0.001) compared with the untreated group, whereas the growth of xenografted tumors had minimal effect by the vector or scramble plasmid delivery (within 10% of variation). Furthermore, the survival of these mice xenografted by various sorted cells was correlated to the tumorigenicity (Figure 5b) . Together, these results demonstrated that Grp78 regulated the aggressiveness of tumorigenicity, which may serve as a molecular target for eradication of refractory cancer.
To examine whether the suppression of tumor growth can be associated with the effect of Grp78 knockdown, the xenografted tumors were dissected to examine Grp78 expression by immunohistochemistry. As shown in Figure 5c , the expression of Grp78 protein was significantly reduced in the siRNA-injected xenografted tumors compared with the higher levels in CD24 À CD44 þ Grp78 þ tumors. In addition, the expression of CSC-associated molecules such as Oct-4, Slug and Nestin was consistently inhibited in response to Grp78 silencing. Therefore, the role of Grp78 in tumorigenicity and survival may act through stem cell regulatory pathways.
DISCUSSION
Aggressive tumors selectively enhance particular characteristics in progressing to a therapy-refractive state. Previous studies have shown that CSCs are preferentially resistant to the effects of both radiation and chemotherapy. [5] [6] [7] [8] [9] [10] The traditionally regarded function of Grp78 in cytoprotection and modulation of chemoresistance has been studied for a decade. 21, 22 This led to our hypothesis that Grp78 may also possess roles in radioresistance and CSC formation, which were demonstrated in the present study. We found that Grp78 þ cells exhibited higher chemo-and radioresistance compared with the parental cells and had comparable levels of CD24 À CD44 þ cells (Figures 2a and b) . The CD24 À CD44 þ Grp78 þ cells, however, showed the highest levels of chemo-and radioresistance, which were dramatically reduced upon Grp78 knockdown (Figures 2a and b) . The role of Grp78 in stress tolerance may be explained by its function in cellular survival and self-renewal capacity (Figure 4a ), both attributes of CSC. Therefore, in addition to the current standard of practice in which adjuvant agents are chosen for their activity against the bulk of the tumor cells, the focus may shift in the future to identifying agents that specifically target the CSC subset. Grp78 may serve as a molecular marker of HN-CSC and a therapeutic target that may be developed for eradicating refractory cancers.
EMT has important roles in embryonic development and the pathogenesis of cancer. It confers tumor plasticity by converting epithelial cells to mesenchymal cells through the functional loss of cell adhesion and acquisition of migratory and invasive properties. This process involves a disassembly of cell-cell and cell-matrix junctions via downregulation of epithelial cell markers (for example, E-cadherin) and upregulation of mesenchymal cell markers and scaffold proteins such as N-cadherin, fibronectin and IQGAP1. [34] [35] [36] Recently, the association of EMT and CSC has been noted. 34, 35 CSC cells isolated from breast cancer tissues express high levels of EMT-associated molecules. Moreover, the induction of EMT in immortalized human mammary epithelial cells led to the generation of a CSC phenotype. In the present study, we found that Grp78 facilitates cancer cell invasion (Figure 3a) , and this Grp78-dependent mobility may occur through an EMT process, as demonstrated by altered expression of the cell-surface molecules E-cadherin, N-cadherin, fibronectin and IQGAP1 (Figures 3b and c) . Thus, Grp78-dependent formation of CSC may proceed through an EMTassociated mechanism.
Several molecules that regulate the cancer stemness phenotype have been identified, including Oct-4, Slug and Nestin. [38] [39] [40] [41] [42] [43] [44] Oct-4 has been suggested as an important factor to regulate the attribute of pluripotent stem cells. 38 Oct-4 was further manifested overexpression in oral and breast cancers and associated with cancer invasion and chemoresistance, characteristics of CSC. [39] [40] [41] Slug has a crucial role during embryonic development and cancer progression through its function in the EMT process. 42, 43 A recent report further showed that in addition to the mediation of cancer invasion, Slug also contributes to chemo-and radioresistance and facilitates the generation of the cancer stemness phenotype of CD24
À CD44 þ cells. 17 Similarly, Nestin has been reported participating in regulation of CSCs in various tissues including head and neck. 41 Therefore, Oct-4, Slug and Nestin may be important molecules participating in CSC conversion in HNC. In the present study, we found that silencing Grp78 substantially inhibited these protein expressions (Figure 4c ), and the reduction of which accompanies the suppression of tumorigenicity (Figure 5c ). These results suggest that Grp78-dependent Figure 4 . Grp78 is required for the maintenance of the stemness phenotype. (a) Grp78 regulates tumor sphere formation as examined on three cell lines, such as Fadu, Detroit and OECM1. Cells were first transfected with total 0.6 mg ml À 1 of plasmids: vector (Vt), Grp78-small interfering RNA (siRNA) (78Si), Grp78-expression plasmid (78FL) or Grp78-rescued plasmids (78Si plus 78FL) for 16 h. When co-transfection with two plasmids, equal amount of each plasmid was added. These cells were then cultured in serum-free medium containing basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) in non-adherent plates. Tumor spheres were observed after 3 weeks of culture and the number of spheres was counted. (b) Grp78 regulates the conversion of CD24 À CD44 þ cells. Three Grp78-enriched cell lines were transfected with vector, Grp78-siRNA (Grp78-Si) or the siRNA following tunicamycin treatment (1.5 mg ml ) for 48 h. The distribution of the CD24 À CD44 þ cell populations were then determined using flow cytometry. (c) Three cell lines were transfected with Grp78-siRNA or the vector plasmid as controls. Cellular proteins were extracted and subjected to western blot analysis for the differential expression of cancer stem cell (CSC)-associated molecules (Oct-4 and Slug) or differentiation markers (CK18 and Involucrin). The relative density in each sample was indicated at the bottom of the band after normalization to the actin level in each individual sample. Vt, vector plasmid-transfected cells; 78Si, Grp78-siRNA-transfected cells.
regulation of EMT and CSC may act through Oct-4-, Slug-and Nestin-signaling pathways.
The identification of more specific CSC markers for HNC is desirable. The CD24 À CD44 þ cells have been reported to exhibit CSC properties in several cancer types including HNC, breast and prostate cancers. [14] [15] [16] [17] [18] [19] [20] The gold standard of proving a CSC phenotype is demonstration of tumorigenic ability, that is, the generation of tumors in immunodeficient mice. To elucidate the CSC potential of differential cell populations in HNC, we performed xenografted tumorigenic analysis. We found that CD24 À CD44 þ cells possess a superior tumorigenic ability compared with CD24 þ CD44 þ or parental cells (Figure 5a ). Moreover, as Grp78 was able to promote CD24 À CD44 þ conversion (Figure 4b ), the CD24 À CD44 þ Grp78 þ cells exhibited superior CSC property and generated a highly aggressive, lethal cancers ( Figure 5 ). Therefore, the CD24 À CD44 þ Grp78 þ phenotype may represent a refractory HN-CSC marker. In conclusion, we have found that Grp78 confers to HN-CSC as demonstrated by actively contribution of EMT, CD24 À CD44 þ cell conversion, stemness property, chemo-radioresistance, cell invasion and the expressions of stem cell regulatory proteins. Silencing Grp78 reverses these malignant phenotypes, suppresses tumorigenic potential and results in better survival in xenografted tumor mice with CD24 À CD44 þ cells. Grp78 may thus serve as a þ Grp78 þ cells) was injected subcutaneously into BALB/C nude mice for 6 weeks. A total of 12 mice was treated in each group. In the Grp78-small interfering RNA (siRNA)-treated group, the CD24 À CD44 þ Grp78 þ cell xenografted mice were also injected intravenously with 25 mg of Grp78-siRNA plasmid in 25 ml of PBS 3 days after tumor cell injection, followed by repeated injections of the same dose twice a week for a total of 12 doses. The tumor volume was calculated as the length Â width Â height. 
CD44
þ Grp78 þ cells, or the CD24 À CD44 þ Grp78 þ tumors with Grp78-siRNA treatment. Six weeks after grafting, the tumors were removed and subjected to immunohistochemical analysis for the specific proteins as indicated. Refractory cancer Poor survival Figure 6 . Schematically illustration of Grp78 as a therapeutic target for refractory head and neck cancer (HNC). Grp78 confers to HN-cancer stem cell (CSC) by actively contribution of epithelial-mesenchymal transition, CD24 À CD44 þ cell conversion, stemness property, chemoradioresistance, cell invasion and the expressions of stem cell regulatory proteins. Silencing Grp78 reverses these malignant phenotypes, suppresses tumorigenic potential and results in better survival in xenografted tumor mice with CD24 À CD44 þ cells. molecular target for the development of therapeutic modality aimed at eradicating refractory HNC ( Figure 6 ).
